J. Thomas Hudson's most recent trade in Abbvie Inc was a trade of 20,634 Common Stock, $0.01 par value done at an average price of $179.0 . Disclosure was reported to the exchange on Feb. 28, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| AbbVie | Thomas J. Hudson | SVP, CSO, GLOBAL RESEARCH | 28 Feb 2024 | 20,634 | 107,267 (0%) | 0% | 179.0 | 3,693,280 | Common Stock, $0.01 par value | |
| AbbVie | Thomas J. Hudson | SVP, CSO, GLOBAL RESEARCH | 15 Feb 2024 | 28,322 | 109,651 (0%) | 0% | 0 | Common Stock, $0.01 par value | ||
| AbbVie | J. Thomas Hudson | SVP, CSO, GLOBAL RESEARCH | 15 Feb 2024 | 18,912 | 18,912 | - | - | Option (Right to Buy) | ||
| AbbVie | Thomas J. Hudson | SVP, CSO, GLOBAL RESEARCH | 15 Feb 2024 | 7,552 | 117,203 (0%) | 0% | 0 | Common Stock, $0.01 par value | ||
| AbbVie | Hudson J. Thomas | SVP, CSO, GLOBAL RESEARCH | 15 Feb 2024 | 5,350 | 122,553 (0%) | 0% | 0 | Common Stock, $0.01 par value | ||
| AbbVie | J. Thomas Hudson | SVP, CSO, GLOBAL RESEARCH | 15 Feb 2024 | 5,348 | 127,901 (0%) | 0% | 0 | Common Stock, $0.01 par value | ||
| AbbVie | Thomas J. Hudson | SVP, R&D AND CSO | 28 Feb 2023 | 27,922 | 81,329 (0%) | 0% | 154.3 | 4,307,806 | Common Stock, $0.01 par value | |
| AbbVie | Thomas J. Hudson | SVP, R&D AND CSO | 16 Feb 2023 | 40,640 | 86,868 (0%) | 0% | 0 | Common Stock, $0.01 par value | ||
| AbbVie | Thomas J. Hudson | SVP, R&D AND CSO | 16 Feb 2023 | 20,256 | 20,256 | - | - | Option (Right to Buy) | ||
| AbbVie | Thomas J. Hudson | SVP, R&D AND CSO | 16 Feb 2023 | 9,481 | 96,349 (0%) | 0% | 0 | Common Stock, $0.01 par value | ||
| AbbVie | Thomas J. Hudson | SVP, R&D AND CSO | 16 Feb 2023 | 7,552 | 103,901 (0%) | 0% | 0 | Common Stock, $0.01 par value | ||
| AbbVie | Thomas J. Hudson | SVP, R&D AND CSO | 16 Feb 2023 | 5,350 | 109,251 (0%) | 0% | 0 | Common Stock, $0.01 par value | ||
| AbbVie | Thomas J. Hudson | SVP, R&D and CSO | 25 Feb 2022 | 13,408 | 46,228 (0%) | 0% | 149.5 | 2,005,032 | Common Stock, $0.01 par value | |
| AbbVie | Thomas J. Hudson | SVP, R&D and CSO | 17 Feb 2022 | 25,394 | 25,394 | - | - | Option (Right to Buy) | ||
| AbbVie | Thomas J. Hudson | SVP, R&D and CSO | 17 Feb 2022 | 11,642 | 41,014 (0%) | 0% | 0 | Common Stock, $0.01 par value | ||
| AbbVie | Thomas J. Hudson | SVP, R&D and CSO | 17 Feb 2022 | 9,483 | 53,027 (0%) | 0% | 0 | Common Stock, $0.01 par value | ||
| AbbVie | Thomas J. Hudson | SVP, R&D and CSO | 17 Feb 2022 | 6,609 | 59,636 (0%) | 0% | 0 | Common Stock, $0.01 par value | ||
| AbbVie | Thomas J. Hudson | SVP, R&D and CSO | 17 Feb 2022 | 2,530 | 43,544 (0%) | 0% | 0 | Common Stock, $0.01 par value | ||
| AbbVie | Thomas J. Hudson | SVP, R&D and CSO | 28 Feb 2021 | 7,740 | 29,372 (0%) | 0% | 107.7 | 833,908 | Common Stock, $0.01 par value | |
| AbbVie | Thomas J. Hudson | SVP, R&D and CSO | 18 Feb 2021 | 37,267 | 37,267 | - | - | Option(right to buy) | ||
| AbbVie | Thomas J. Hudson | SVP, R&D and CSO | 18 Feb 2021 | 9,483 | 37,112 (0%) | 0% | 0 | Common Stock, $0.01 par value | ||
| AbbVie | Thomas J. Hudson | SVP, R&D and CSO | 18 Feb 2021 | 4,216 | 23,859 (0%) | 0% | 0 | Common Stock, $0.01 par value | ||
| AbbVie | Thomas J. Hudson | SVP, R&D and CSO | 18 Feb 2021 | 2,530 | 27,629 (0%) | 0% | 0 | Common Stock, $0.01 par value | ||
| AbbVie | Thomas J. Hudson | SVP, R&D and CSO | 18 Feb 2021 | 1,240 | 25,099 (0%) | 0% | 0 | Common Stock, $0.01 par value |